ReviewJournal of neuro-oncology2025
The evolution of stereotactic radiosurgery for vestibular schwannomas: recent evidence and outcomes.
Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pseudoprogression in Koos grade 4 vestibular schwannomas following stereotactic radiosurgery: temporal dynamics and radiological predictors.Journal of neuro-oncology · 2026Article
- Vestibular schwannoma: genetic and epigenetic mechanisms, hearing loss, and emerging therapies.Journal of neuro-oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVestibular schwannomas (VS) are benign tumors of the vestibular nerve, increasingly detected due to improved and more frequent neuroimaging studies. A summary of the evolution of radiosurgery for VS management is undertaken.
methodsWe broadly review the history and current state of stereotactic radiosurgery in the management of vestibular schwannomas.
resultsManagement includes observation, microsurgical resection, and stereotactic radiosurgery (SRS). First used for VS in the late 1960s, SRS achieves > 90% tumor control with safe complication profile. In small VS, early SRS reduces tumor progression and the need for delayed intervention with better cranial nerve outcomes compared to observation. For large VS, SRS provides high tumor control with exceedingly lower complications than surgery in select cases. In neurofibromatosis type 2 (NF2), SRS offers durable tumor control, though hearing preservation and clinical outcomes varies as it contingent on the complex clinical presentation and disease burden, a unique challenge of NF2 patients. Comparative studies and randomized trials reinforce SRS as an effective, minimally invasive treatment with superior long-term tumor control and lower morbidity. Hearing preservation depends on cochlear radiation dose, tumor volume, degree of hearing at time of intervention, age, and tumor morphology. In NF2 and large VS, careful patient selection is critical.
conclusionStereotactic radiosurgery is playing an increasingly important role in the management of patients with vestibular schwannomas. Future research will refine dose optimization, patient selection, and long-term functional outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.